PHARMACEUTICAL IP

  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional IP counsel
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional IP counsel
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional IP counsel
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

CJEU clarifies jurisdiction rules for European patent enforcement: BSH Hausgeräte vs. Electrolux AB

  • Sector: Patent law
  • 1st March 2025

Originally posted on IPKat.

Earlier this week the CJEU provided its ruling in the highly anticipated case of BSH Hausgeräte v. Electrolux (Case C-339/22, February 2025). The case addressed longstanding questions about the jurisdiction of European courts when patent invalidity is raised as a defence in an infringement case. The CJEU found that national courts maintain jurisdiction over infringement claims against defendants domiciled in their territory, even when invalidity of foreign patents is raised. The case follows a recent UPC case that tackled similar questions relating to the jurisdiction of the UPC to hear cases relating to UK patent infringement (UPC_CFI_355/2023). 

BSH sued Electrolux (a Swedish company) in Sweden. BSH alleged that Electrolux infringed its EP1434512 (relating to vacuum cleaners) which was validated in certain EU states and Turkey. BSH requested an injunction and damages for infringement in all these countries. In response, Electrolux argued that the patents were invalid and that the court had no jurisdiction, claiming that Article 24(4) of the Brussels Regulation meant that if invalidity was raised, the court would lose jurisdiction over the infringement case. 

Article 4(1) Brussels I Regulation (Regulation 1215/2012) states that “persons domiciled in a Member State shall, whatever their nationality, be sued in the courts of that Member State“. 

Article 24 Brussels I Regulation (Regulation 1215/2012) states that: “The following courts of a Member State shall have exclusive jurisdiction, regardless of the domicile of the parties […] (4) in proceedings concerned with the registration or validity of patents […] irrespective of whether the issue is raised by way of an action or as a defence, the courts of the Member State in which the deposit or registration has been applied for“. 

The Swedish court of appeal referred the following questions to the CJEU: 

1. Does a court that has jurisdiction for patent infringement under Article 4(1) of the Regulation lose its jurisdiction if the validity of the patent is contested? Or does the court only have jurisdiction to decide on validity?

2. Is it relevant whether national law requires a separate invalidity action?

3. Does Article 24(4) of the Regulation also apply to courts of third countries (here: Turkey)?

The CJEU ruled in BSH’s favour, finding that Article 24(4) should be strictly interpreted as an exception to the general rule of Article 4(1). The CJEU particularly found that whilst national courts cannot rule on the validity of foreign patents, they can continue hearing infringement claims, with the option to stay proceedings if there’s a reasonable possibility the patent might be invalidated in its country of registration. The CJEU concluded that under Article 4(1), the court in which the defendant is domiciled remains competent to decide on patent infringement, even if the patent was granted in another European state and even if the validity of the patent is contested. At the same time, the CJEU confirmed the exclusive jurisdiction of the courts of the patent-granting state to decide on the validity of the patent. 

Therefore, according to the CJEU decision, EU courts (including the UPC) can look at the question of validity of European patents in non-EU countries to determine infringement issues. However, the EU court’s decision will not affect the existence or content of the patent in that third country (para. 74).

Related insights...

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, The Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.

When do you file for a drug combination invention? (T592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 

Patenting the use of medical devices (T0941/24)

  • 26th June 2026
Patenting medical devices in Europe is challenging. First, there is the problem that medical use claims are not permitted for medical devices, whilst simultaneously methods of treatment or surgery using a device are excluded from patentability. 

BREAKING: Imminent new referral to the EBA on the relevance of G1/24 to added matter

  • 6th May 2026
The Board of Appeal in T 873/24 has decided to refer questions to the Enlarged Board of Appeal (EBA) on the application of G1/24 (claim interpretation) to the assessment of added matter.

Description amendments can extend protection (T 439/22)

  • 3rd April 2026
The comments space for the last IPKat article on claim interpretation/description amendments appears to have maxed out. Sorry everyone, but maybe it’s for the best. However, fear not, we now have a new decision to restart the debate!

The validity and value of cell therapy safety protocol inventions (T 1555/23)

  • 11th March 2026
The patent in T 1555/23 is impressively broad. The claims covered a medical use invention comprising treating the side effects of CAR-T cell therapy using the now industry-standard class of cytokine inhibitor. The claim was not limited to any particular CAR-T cell therapy, target, type of cancer or specific inhibitor.

G 1/25 (description amendments) amicus curiae: The battle lines are drawn

  • 4th March 2026
If you want to start an argument amongst European patent attorneys, just mention description amendments. As the comments on this and other blogs attest, adaptation of the description is a highly divisive issue and the debate can get decidedly heated (with our US colleagues looking on with bemusement).

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.

Non-reproducible products can be the closest prior art (T 1719/21)

  • 17th February 2026
G 1/23 establishes that products made available to the public are prior art in Europe, regardless of reproducibility. While this simplifies novelty, focusing strictly on disclosure dates, it complicates inventive step assessments. Notably, T 1719/21 questions whether these non-reproducible products can serve as the “closest prior art” in the EPO’s problem-solution approach.

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us